A couple of naive (and admittedly political) questions I didn't see addressed in the article... Is there any way to find out how much of the R&D money for the

A couple of naive (and admittedly political) questions I didn't see addressed in the article... Is there any way to find out how much of the R&D money for the medicine came from public funding? I can understand if the information is simply not available because it comes from a larger pool of R&D monies. > Erenumab is now expected to be considered by English and Scottish health agencies to assess whether it is appropriate for NHS use. Curious whether it has to be approved by the EU first before its use by NHS is allowed (or if its assessment is even worth it until EU approval occurs). Also curious whether "appropriate for NHS use" means at no cost to migraine sufferers.